216 related articles for article (PubMed ID: 32606741)
1. β-Elemene Enhances the Chemotherapeutic Effect of 5-Fluorouracil in Triple-Negative Breast Cancer via PI3K/AKT, RAF-MEK-ErK, and NF-κB Signaling Pathways.
Su P; Ahmad B; Zou K; Zou L
Onco Targets Ther; 2020; 13():5207-5222. PubMed ID: 32606741
[TBL] [Abstract][Full Text] [Related]
2. Melatonin synergizes the chemotherapeutic effect of 5-fluorouracil in colon cancer by suppressing PI3K/AKT and NF-κB/iNOS signaling pathways.
Gao Y; Xiao X; Zhang C; Yu W; Guo W; Zhang Z; Li Z; Feng X; Hao J; Zhang K; Xiao B; Chen M; Huang W; Xiong S; Wu X; Deng W
J Pineal Res; 2017 Mar; 62(2):. PubMed ID: 27865009
[TBL] [Abstract][Full Text] [Related]
3. Down-regulating IL-6/GP130 targets improved the anti-tumor effects of 5-fluorouracil in colon cancer.
Li S; Tian J; Zhang H; Zhou S; Wang X; Zhang L; Yang J; Zhang Z; Ji Z
Apoptosis; 2018 Jun; 23(5-6):356-374. PubMed ID: 29777330
[TBL] [Abstract][Full Text] [Related]
4.
Zhang W; Ou L; Peng C; Sang S; Feng Z; Zou Y; Yuan Y; Li H; Zhang G; Yao M
Heliyon; 2023 Jun; 9(6):e16798. PubMed ID: 37484409
[TBL] [Abstract][Full Text] [Related]
5. Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.
Van Swearingen AED; Sambade MJ; Siegel MB; Sud S; McNeill RS; Bevill SM; Chen X; Bash RE; Mounsey L; Golitz BT; Santos C; Deal A; Parker JS; Rashid N; Miller CR; Johnson GL; Anders CK
Neuro Oncol; 2017 Oct; 19(11):1481-1493. PubMed ID: 28486691
[TBL] [Abstract][Full Text] [Related]
6. AKR1B10 promotes breast cancer cell proliferation and migration via the PI3K/AKT/NF-κB signaling pathway.
Qu J; Li J; Zhang Y; He R; Liu X; Gong K; Duan L; Luo W; Hu Z; Wang G; Xia C; Luo D
Cell Biosci; 2021 Aug; 11(1):163. PubMed ID: 34419144
[TBL] [Abstract][Full Text] [Related]
7. Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib.
Wang X; Song H; Yu Q; Liu Q; Wang L; Liu Z; Yu Z
Oncol Rep; 2015 Feb; 33(2):526-32. PubMed ID: 25501339
[TBL] [Abstract][Full Text] [Related]
8. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
9. Elevated estrogen receptor β expression in triple negative breast cancer cells is associated with sensitivity to doxorubicin by inhibiting the PI3K/AKT/mTOR signaling pathway.
Lei S; Fan P; Wang M; Zhang C; Jiang Y; Huang S; Fang M; He Z; Wu A
Exp Ther Med; 2020 Aug; 20(2):1630-1636. PubMed ID: 32742395
[TBL] [Abstract][Full Text] [Related]
10. PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathway.
Hu H; Zhu J; Zhong Y; Geng R; Ji Y; Guan Q; Hong C; Wei Y; Min N; Qi A; Zhang Y; Li X
Ann Transl Med; 2021 Mar; 9(5):410. PubMed ID: 33842631
[TBL] [Abstract][Full Text] [Related]
11. Dual Inhibition of AKT and MEK Pathways Potentiates the Anti-Cancer Effect of Gefitinib in Triple-Negative Breast Cancer Cells.
You KS; Yi YW; Cho J; Seong YS
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33801977
[TBL] [Abstract][Full Text] [Related]
12. Integrin β1, myosin light chain kinase and myosin IIA are required for activation of PI3K-AKT signaling following MEK inhibition in metastatic triple negative breast cancer.
Choi C; Kwon J; Lim S; Helfman DM
Oncotarget; 2016 Sep; 7(39):63466-63487. PubMed ID: 27563827
[TBL] [Abstract][Full Text] [Related]
13. Radix Tetrastigma Extracts Enhance the Chemosensitivity in Triple-Negative Breast Cancer Via Inhibiting PI3K/Akt/mTOR-Mediated Autophagy.
Zhang S; Cui T; Duan Y; Zhang H; Wang B; Chen H; Ni J; Shen Y; Xiao-Ai Lv
Clin Breast Cancer; 2022 Feb; 22(2):89-97. PubMed ID: 34535390
[TBL] [Abstract][Full Text] [Related]
14. EGFR and MEK Blockade in Triple Negative Breast Cancer Cells.
Maiello MR; D'Alessio A; Bevilacqua S; Gallo M; Normanno N; De Luca A
J Cell Biochem; 2015 Dec; 116(12):2778-85. PubMed ID: 25959272
[TBL] [Abstract][Full Text] [Related]
15. Programmed death-ligand 1 signaling and expression are reversible by lycopene via PI3K/AKT and Raf/MEK/ERK pathways in tongue squamous cell carcinoma.
Peng M; Fan S; Li J; Zhou X; Liao Q; Tang F; Liu W
Genes Nutr; 2022 Feb; 17(1):3. PubMed ID: 35164673
[TBL] [Abstract][Full Text] [Related]
16. β-elemene enhances cisplatin-induced apoptosis in bladder cancer cells through the ROS-AMPK signaling pathway.
Gan D; He W; Yin H; Gou X
Oncol Lett; 2020 Jan; 19(1):291-300. PubMed ID: 31897141
[TBL] [Abstract][Full Text] [Related]
17. Synergistic Role of Thymoquinone on Anticancer Activity of 5-Fluorouracil in Triple Negative Breast Cancer Cells.
Zheng M; Mei Z; Junaid M; Tania M; Fu J; Chen HC; Khan MA
Anticancer Agents Med Chem; 2022; 22(6):1111-1118. PubMed ID: 34170813
[TBL] [Abstract][Full Text] [Related]
18. Anlotinib Overcomes Multiple Drug Resistant Colorectal Cancer Cells via Inactivating PI3K/AKT Pathway.
Lan W; Zhao J; Chen W; Shang H; Peng J; Lin J
Anticancer Agents Med Chem; 2021; 21(15):1987-1995. PubMed ID: 33438566
[TBL] [Abstract][Full Text] [Related]
19. LY294002 may overcome 5-FU resistance via down-regulation of activated p-AKT in Epstein-Barr virus-positive gastric cancer cells.
Shin JY; Kim JO; Lee SK; Chae HS; Kang JH
BMC Cancer; 2010 Aug; 10():425. PubMed ID: 20704765
[TBL] [Abstract][Full Text] [Related]
20. [Anti-proliferation effect of sorafenib in combination with 5-FU for hepatocellular carcinoma in vitro: antagonistic performance and mechanism].
Deng LF; Wang YH; Jia QA; Ren ZG; Shen HJ; Sun XJ; Li JH
Zhonghua Gan Zang Bing Za Zhi; 2013 Nov; 21(11):845-9. PubMed ID: 24331695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
